Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
BMJ Open|September 29, 2023
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapyHongye Ren, Sasha Berry, Samuel Joseph Paul Malkin, et al.
Journal of Affective Disorders|May 21, 2022
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illnessDavid S Baldwin, Oscar Necking, Simon Nitschky Schmidt, et al.
Frontiers in Psychiatry|January 23, 2023
Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE studyGregory Mattingly, Elizabeth Brunner, Lambros Chrones, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 21, 2025
Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in EnglandDerek Connolly, Edward Collins, Hongye Ren, et al.
Neuropsychiatric Disease and Treatment|September 30, 2021
Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative StudyBernhard T Baune, Ioana Florea, Bjarke Ebert, et al.
Journal of Medical Economics|August 24, 2018
Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in ChinaGuohai Shi, Sang Hee Park, Hongye Ren, et al.
Neuropsychiatric Disease and Treatment|November 10, 2022
Validation and Functional Relevance of the Short Form of the Perceived Deficits Questionnaire for Depression for Japanese Patients with Major Depressive DisorderTomiki Sumiyoshi, Hiroyuki Uchida, Koichiro Watanabe, et al.
Diabetes & Vascular Disease Research|December 19, 2023
Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysisMarc Evans, Paul Kuodi, Chisom Joyqueenet Akunna, et al.
Value in Health Regional Issues|April 11, 2022
Health-Related Quality of Life Over 6 Months in Patients With Major Depressive Disorder Who Started Antidepressant MonotherapyShinichi Noto, Mayumi Wake, Izumi Mishiro, et al.
Neuropsychiatric Disease and Treatment|August 16, 2022
Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE StudySergio De Filippis, Anna Pugliese, Michael Cronquist Christensen, et al.
Pageof 3